ABCL
AbCellera Biologics Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+77/100
Last price
13.27
▼ 0.51 (3.70%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.85
Prev close
13.78
Day high
14.53
Day low
12.93
Volume
9.79M
Market cap
$4.26B
P/E (TTM)
—
52W range
2.75 – 15.02
Day trading desk
Gap from prior close
+0.51%
Prior close 13.78
VWAP
13.27
+0.04% from price
Relative volume
2.86×
Unusually busy
Session range
12.35%
12.93 – 14.53
Position in range
21%
Near session low
ATR (14D)
0.88
6.62% of price
Prior day high
13.88
PDH
Prior day low
13.21
PDL
Bid / ask spread
—
Quote not published
Session volume
19.11M
Avg 6.69M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-11.27%
-13.2%
1M
+15.05%
+13.9%
3M
+85.21%
+80.7%
6M
+298.48%
+280.3%
YTD
+284.50%
+270.3%
1Y
+122.88%
+106.5%
3Y
+185.87%
+103.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
11 more panels on ABCL open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
66.65M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 24, 26 | HAYDEN MICHAEL REUBEN Director |
BUY | 53.61K | $570.44K | Indirect |
| Aug 18, 26 | MONTALBANO JOHN S. Director |
BUY | 10.00K | $110.30K | Direct |
| Aug 14, 26 | BOOTH ANDREW Chief Financial Officer |
BUY | 37.20K | $383.90K | Direct |
| Aug 12, 26 | HAYDEN MICHAEL REUBEN Director |
BUY | 46.39K | $481.03K | Indirect |
| Aug 11, 26 | HAYDEN MICHAEL REUBEN Director |
STOCK | 50.00K | $0 | Indirect |
| Jun 3, 26 | BOOTH ANDREW Chief Financial Officer |
CONVERSION | 250.00K | $47.50K | Direct |
| May 14, 26 | MONTALBANO JOHN S. Director |
BUY | 20.00K | $95.40K | Direct |
| Feb 27, 26 | THERMOPYLAE HOLDINGS, LTD. Beneficial Owner of more than 10% of a Class of Security |
BUY | 38.00K | $130.72K | Direct |
| Feb 27, 26 | BOOTH ANDREW Chief Financial Officer |
BUY | 42.60K | $145.69K | Direct |
| Feb 26, 26 | THERMOPYLAE HOLDINGS, LTD. Beneficial Owner of more than 10% of a Class of Security |
BUY | 177.46K | $580.28K | Direct |
| Dec 18, 25 | THERMOPYLAE HOLDINGS, LTD. Beneficial Owner of more than 10% of a Class of Security |
STOCK | 225.00K | $0 | Direct |
| Nov 26, 25 | MONTALBANO JOHN S. Director |
BUY | 50.00K | $178.46K | Direct |
| Mar 11, 25 | THERMOPYLAE HOLDINGS, LTD. Beneficial Owner of more than 10% of a Class of Security |
BUY | 343.63K | $742.24K | Direct |
| Mar 10, 25 | MONTALBANO JOHN S. Director |
BUY | 25.00K | $57.50K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BOOTH ANDREW |
Chief Financial Officer | 613.76K | Purchase |
HANSEN CARL L.G. |
Chief Executive Officer | 56.98M | Conversion of Exercise of derivative security |
HAYDEN MICHAEL REUBEN |
Director | — | Purchase |
MONTALBANO JOHN S. |
Director | 256.00K | Purchase |
THERMOPYLAE HOLDINGS, LTD. |
Beneficial Owner of more than 10% of a Class of Security | 56.13M | Purchase |
Fundamentals
Market cap$4.26B
Enterprise value$3.63B
Revenue (TTM)$66.17M
Gross profit$-131.60M
EBITDA$-199.96M
Net income$-164.66M
EPS (TTM)$-0.51
Free cash flow$-46.43M
Total cash$540.10M
Total debt$135.62M
Book value / share$2.92
Shares outstanding324.05M
Float209.04M
Short % of float13.34%
Dividend yield0.00%
Beta (5Y)1.41
Valuation & profitability ratios
Trailing P/E—
Forward P/E-16.86
PEG ratio—
Price / sales—
Price / book4.50
EV / revenue54.82
EV / EBITDA-18.14
Gross margin-198.88%
Operating margin-1550.05%
Profit margin-248.84%
Return on equity-17.30%
Return on assets-10.39%
Debt / equity15.14
Current ratio12.77
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $75.13M | $28.83M | $38.02M | $485.42M | — | +160.6% |
| Operating revenue | $75.13M | $28.83M | $38.02M | $485.42M | — | +160.6% |
| Cost of revenue | — | $0 | $0 | $66.44M | $45.52M | — |
| Gross profit | — | $28.83M | $38.02M | $418.99M | $329.69M | — |
| Research & development | $186.83M | $167.26M | $175.66M | $107.88M | — | +11.7% |
| Selling, general & admin | $83.23M | $85.49M | $75.18M | $66.75M | — | -2.6% |
| Total operating expense | $278.34M | $329.98M | $261.08M | $191.92M | — | -15.6% |
| Operating income | -$203.21M | -$301.15M | -$223.05M | $227.06M | — | +32.5% |
| Net interest income | $28.33M | $38.47M | $42.25M | $16.08M | — | -26.4% |
| Pre-tax income | -$177.59M | -$200.40M | -$174.03M | $239.10M | — | +11.4% |
| Tax provision | -$31.18M | -$37.54M | -$27.63M | $80.58M | — | +16.9% |
| Net income | -$146.41M | -$162.86M | -$146.40M | $158.52M | — | +10.1% |
| Net income to common | -$146.41M | -$162.86M | -$146.40M | $158.52M | — | +10.1% |
| Basic EPS | -0.49 | -0.55 | -0.51 | 0.56 | — | +10.9% |
| Diluted EPS | -0.49 | -0.55 | -0.51 | 0.50 | — | +10.9% |
| EBIT | -$203.21M | -$301.15M | -$223.05M | $227.06M | — | +32.5% |
| EBITDA | -$174.39M | -$204.15M | -$192.16M | $260.17M | — | +14.6% |
| Basic shares | 298.71M | 294.33M | 289.17M | 285.06M | — | +1.5% |
| Diluted shares | 298.71M | 294.33M | 289.17M | 314.83M | — | +1.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $128.51M | $156.32M | $133.32M | $386.54M | -17.8% |
| Cash & short-term investments | $533.83M | $625.61M | $760.59M | $886.49M | -14.7% |
| Accounts receivable | $58.29M | $33.62M | $30.59M | $38.59M | +73.4% |
| Inventory | $6.34M | $0 | $1.11M | $1.53M | — |
| Total current assets | $728.23M | $751.37M | $871.99M | $1.03B | -3.1% |
| Property, plant & equipment | $428.00M | $340.43M | $287.70M | $217.25M | +25.7% |
| Goodwill & intangibles | $86.19M | $89.92M | $168.23M | $179.31M | -4.2% |
| Total assets | $1.36B | $1.36B | $1.49B | $1.54B | -0.3% |
| Total current liabilities | $64.31M | $76.61M | $119.01M | $118.32M | -16.1% |
| Total debt | $143.22M | $65.36M | $77.38M | $82.26M | +119.1% |
| Total liabilities | $390.05M | $304.47M | $335.78M | $307.63M | +28.1% |
| Retained earnings | -$29.48M | $116.93M | $279.79M | $426.19M | -125.2% |
| Shareholder equity | $966.90M | $1.06B | $1.15B | $1.23B | -8.4% |
| Working capital | $663.92M | $674.76M | $752.97M | $907.17M | -1.6% |
| Net tangible assets | $880.72M | $966.16M | $984.09M | $1.05B | -8.8% |
| Shares issued | 300.60M | 295.76M | 290.82M | 286.85M | +1.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$146.41M | -$162.86M | -$146.40M | $158.52M | +10.1% |
| Depreciation & amortisation | $28.82M | $97.00M | $30.89M | $33.10M | -70.3% |
| Stock-based compensation | $55.79M | $67.58M | $64.18M | $49.48M | -17.4% |
| Change in working capital | -$70.69M | -$25.84M | $13.22M | $29.82M | -173.6% |
| Operating cash flow | -$131.29M | -$108.56M | -$43.88M | $277.36M | -20.9% |
| Capital expenditure | -$42.77M | -$78.40M | -$76.95M | -$72.66M | +45.4% |
| Investing cash flow | $87.75M | $121.41M | -$221.11M | -$352.63M | -27.7% |
| Financing cash flow | $14.08M | $12.77M | $10.36M | -$1.63M | +10.3% |
| Free cash flow | -$174.07M | -$186.95M | -$120.82M | $204.70M | +6.9% |
| End cash position | $155.25M | $183.62M | $160.61M | $414.65M | -15.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $4.05M | $8.31M | $44.85M | $8.96M | $17.08M | — | -51.3% |
| Operating revenue | $4.05M | $8.31M | $44.85M | $8.96M | $17.08M | — | -51.3% |
| Research & development | $45.99M | $46.66M | $50.09M | $55.03M | $39.21M | — | -1.4% |
| Selling, general & admin | $13.85M | $12.33M | $17.22M | $24.96M | $21.99M | — | +12.3% |
| Total operating expense | $62.97M | $61.49M | $70.12M | $82.50M | $62.98M | — | +2.4% |
| Operating income | -$58.92M | -$53.18M | -$25.27M | -$73.55M | -$45.89M | — | -10.8% |
| Net interest income | -$42.00K | $3.64M | $5.92M | $6.76M | $9.55M | — | -101.2% |
| Pre-tax income | -$58.97M | -$49.54M | -$19.50M | -$68.77M | -$36.34M | — | -19.0% |
| Tax provision | -$3.54M | -$6.37M | -$10.55M | -$11.65M | -$1.62M | — | +44.5% |
| Net income | -$55.43M | -$43.16M | -$8.95M | -$57.12M | -$34.73M | — | -28.4% |
| Net income to common | -$55.43M | -$43.16M | -$8.95M | -$57.12M | -$34.73M | — | -28.4% |
| Basic EPS | -0.18 | -0.14 | — | -0.19 | -0.12 | -0.15 | -28.6% |
| Diluted EPS | -0.18 | -0.14 | — | -0.19 | -0.12 | -0.15 | -28.6% |
| EBIT | -$58.92M | -$53.18M | -$25.27M | -$73.55M | -$45.89M | — | -10.8% |
| EBITDA | -$50.14M | -$44.52M | -$17.35M | -$66.31M | -$38.83M | — | -12.6% |
| Basic shares | 305.56M | 303.07M | — | 298.88M | 298.51M | 297.69M | +0.8% |
| Diluted shares | 305.56M | 303.07M | — | 298.88M | 298.51M | 297.69M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $120.06M | $77.06M | $128.51M | $83.16M | $92.44M | +55.8% |
| Cash & short-term investments | $540.10M | $504.73M | $533.83M | $495.67M | $553.08M | +7.0% |
| Accounts receivable | $18.60M | $36.76M | $58.29M | $41.46M | $47.31M | -49.4% |
| Inventory | $7.58M | $7.86M | $6.34M | — | — | -3.6% |
| Total current assets | $679.23M | $664.60M | $728.23M | $695.14M | $742.14M | +2.2% |
| Property, plant & equipment | $416.68M | $422.81M | $428.00M | $427.36M | $424.02M | -1.4% |
| Goodwill & intangibles | $84.34M | $85.27M | $86.19M | $87.13M | $88.07M | -1.1% |
| Total assets | $1.31B | $1.31B | $1.36B | $1.36B | $1.40B | +0.0% |
| Total current liabilities | $53.19M | $47.29M | $64.31M | $68.80M | $67.02M | +12.5% |
| Total debt | $135.62M | $140.18M | $143.22M | $142.22M | $142.08M | -3.3% |
| Total liabilities | $411.56M | $369.03M | $390.05M | $391.95M | $394.99M | +11.5% |
| Retained earnings | -$128.07M | -$72.65M | -$29.48M | -$20.54M | $36.58M | -76.3% |
| Shareholder equity | $896.02M | $938.08M | $966.90M | $964.04M | $1.01B | -4.5% |
| Working capital | $626.04M | $617.30M | $663.92M | $626.34M | $675.12M | +1.4% |
| Net tangible assets | $811.68M | $852.82M | $880.72M | $876.91M | $919.01M | -4.8% |
| Shares issued | 306.47M | 303.95M | 300.60M | 299.01M | 298.65M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$55.43M | -$43.16M | -$8.95M | -$57.12M | -$34.73M | -28.4% |
| Depreciation & amortisation | $8.78M | $8.65M | $7.92M | $7.24M | $7.06M | +1.5% |
| Stock-based compensation | $12.29M | $12.01M | $12.90M | $13.89M | $14.21M | +2.3% |
| Change in working capital | $55.64M | -$13.40M | -$46.22M | -$18.14M | -$16.80M | +515.1% |
| Operating cash flow | $25.92M | -$33.52M | -$34.74M | -$52.59M | -$32.40M | +177.3% |
| Capital expenditure | -$2.13M | -$3.83M | -$9.84M | -$8.93M | -$13.37M | +44.3% |
| Investing cash flow | $11.34M | -$25.08M | $75.14M | $36.49M | -$31.81M | +145.2% |
| Financing cash flow | $6.39M | $7.19M | $4.12M | $7.37M | -$3.38M | -11.1% |
| Free cash flow | $23.79M | -$37.35M | -$44.59M | -$61.52M | -$45.77M | +163.7% |
| End cash position | $147.03M | $103.80M | $155.25M | $110.45M | $119.73M | +41.6% |
Options analytics
Put / call volume
0.37
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-92.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
2.27K
Contracts, this expiry
Put volume
838
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
3.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.17 | -0.18 | -9.1% |
| Mar 2026 | -0.20 | -0.14 | +29.1% |
| Dec 2025 | -0.18 | -0.03 | +83.3% |
| Sep 2025 | -0.16 | -0.19 | -17.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.18 | 5 | $6.22M | -30.6% |
| Next quarter | -0.18 | 5 | $7.00M | -84.4% |
| Current year | -0.68 | 7 | $26.36M | -64.9% |
| Next year | -0.78 | 6 | $28.44M | +7.9% |
Analyst targets & ownership
Mean target$16.70
High target$30.00
Low target$9.00
Implied upside25.84%
Analyst count10
ConsensusSTRONG BUY
Strong buy / Buy2 / 8
Hold1
Sell / Strong sell0 / 0
Held by insiders21.74%
Held by institutions37.19%
Institutions holding197
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.56
-2.11% from price
SMA 20
12.64
+4.00% from price
SMA 50
10.86
+21.10% from price
SMA 100
8.41
+57.73% from price
SMA 200
6.08
+116.20% from price
EMA 12
13.34
-0.50% from price
EMA 26
12.49
+6.21% from price
EMA 50
11.15
+19.07% from price
RSI (14)
56.8
Neutral
MACD (12,26,9)
0.84
Hist -0.04
ATR (14)
0.88
6.68% of price
Realised vol 30D
75.9%
Annualised
Bollinger upper
15.08
20, 2σ
Bollinger lower
10.21
20, 2σ
50 / 200 cross
Golden
10.86 vs 6.08
Trend bias
Above 200
+116.20%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.49
More volatile than market
Correlation to SPY
0.38
Loosely linked
Realised vol 30D
75.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-54.9%
Peak to trough
Max drawdown 5Y
-89.1%
Peak to trough
ATR 14
0.88
6.68% of price
Beta (reported)
1.41
5Y monthly, from filing
Short interest
Shares short
33.93M
Prior 41.34M
Change vs prior
-17.9%
Shorts covering
% of float
13.34%
Elevated
% of shares out
10.47%
Against total outstanding
Days to cover
6.4
Crowded exit
Float
209.04M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 29, 26 | JP Morgan | INITIATED | — | Overweight |
| Aug 11, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Stifel | MAINTAINED | Buy | Buy |
| Aug 6, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Jul 7, 26 | Benchmark | UPGRADE | Hold | Buy |
| May 5, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Apr 10, 26 | Jones Trading | INITIATED | — | Buy |
| Nov 7, 25 | Leerink Partners | DOWNGRADE | Outperform | Market Perform |
| Aug 8, 25 | Stifel | MAINTAINED | Buy | Buy |
| Jul 14, 25 | Keybanc | MAINTAINED | Overweight | Overweight |
| May 16, 25 | Truist Securities | MAINTAINED | Buy | Buy |
| May 9, 25 | Stifel | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-10
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-06
Corporate Changes & Voting Matters
8-K · 2026-06-17
Corporate Changes & Voting Matters
8-K · 2026-06-12
Headlines
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire · 5d ago
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
CNW Group · 6d ago
Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
PR Newswire · 7d ago
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today?
Stocktwits · 7d ago
JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target
MT Newswires · 8d ago
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
Zacks · 15d ago
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026
Business Wire · 20d ago
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026
Business Wire · 34d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.